A Prospective, Randomized, Blind, Controlled Multicenter Clinical Study Comparing the Effectiveness of Preventive Ventricular Arrhythmia Ablation on the Prognosis After Left Ventricular Assist Device (LVAD) Surgery. (PAVA-LVAD)
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
Anhui
-
Hefei, Anhui, China
- 5thBuilding, 9thFloor, High-tech Campus of the First Affiliated Hospital of Anhui Medical University
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
- 1.voluntary and with the provision of an informed consent form 2.males or females aged 18 years or older 3.all patients with acute and critical or chronic advanced heart failure who have failed to respond to standardized oral medication and are scheduled to undergo artificial heart implantation surgery
Exclusion Criteria:
1.The left ventricular assist system is prohibited for patients who cannot tolerate anticoagulant therapy or who are allergic to anticoagulant treatment.
2.Doctors with sufficient experience will make a comprehensive judgment based on the patient's physical condition, body surface area, and the anatomical-related conditions of the planned implantation site, and determine those who are not suitable for the implantation procedure.
3.Pregnant women. 4.Systemic active infection. 5.Patients in a state of brain death. 6.Irreversible severe liver or kidney dysfunction. 7.Having a history of severe chronic obstructive pulmonary disease (COPD) or restrictive lung disease.
8.primary pulmonary hypertension. 9.Having a confirmed and untreated history of abdominal or thoracic aortic aneurysm with a diameter greater than 5 cm.
10.Patients with severe atherosclerotic plaques in the aorta. 11.Having mental disorders/impairments, irreversible cognitive dysfunction, or social-psychological problems, which makes it possible for the patient to fail to comply with the application management regulations of the implanted left ventricular assist device.
12.Preoperative conditions included end-stage organ failure, such as renal failure (requiring hemodialysis), liver failure, respiratory failure; and concurrent malignant tumors or any severe accompanying diseases with an expected lifespan of less than 3 years.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Dobro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: preventive ablation group
for patients undergoing LVAD surgery while also undergoing prophylactic ablation of ventricular arrhythmias at the same time
|
for patients undergoing LVAD surgery while also undergoing prophylactic ablation of ventricular arrhythmias at the same time
|
|
Sem intervenção: the control group without any treatment
no intervention measures
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
persistent ventricular tachycardia / ventricular fibrillation
Prazo: Continuous electrocardiogram monitoring for 30 days after surgery
|
Electrocardiogram monitoring was conducted daily for the patients 30 days after the surgery.
Data were uploaded daily and the frequency of arrhythmia occurrences was statistically analyzed.
|
Continuous electrocardiogram monitoring for 30 days after surgery
|
|
all-cause mortality
Prazo: Within 30 days after the operation
|
Conduct a 30-day follow-up visit for the patients, and collect the time and cause of death.
|
Within 30 days after the operation
|
|
mechanical thrombus
Prazo: Within 30 days after the operation
|
Electrocardiogram monitoring was performed daily on the patients 30 days after the surgery.
When thrombosis occurred, the left heart assist device would give an alarm to alert.
In some cases, autopsy could be conducted to obtain the results.
|
Within 30 days after the operation
|
|
right heart failure
Prazo: Within 30 days after the operation
|
Conduct a 30-day follow-up visit for the patients, and collect the time and cause of right heart failure.
|
Within 30 days after the operation
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
all-cause mortality
Prazo: semi-annually, for a total of three years
|
Patients are followed up in the outpatient department or by phone every six months to collect death-related records such as death certificates and discharge summaries.
|
semi-annually, for a total of three years
|
|
mechanical thrombus
Prazo: semi-annually, for a total of three years
|
The artificial heart device implanted in the patient will continuously monitor.
When a thrombosis occurs, the left heart assist device will alert and remotely contact the medical team.
In some cases, this information can be obtained through autopsy after death.
|
semi-annually, for a total of three years
|
|
stroke
Prazo: semi-annually, for a total of three years
|
Patients are followed up in the outpatient department or by phone every six months, and the necessary medical history records, imaging reports (such as head CT or MRI), and other original materials are collected.
|
semi-annually, for a total of three years
|
|
Hospitalization or emergency visit due to heart failure
Prazo: semi-annually, for a total of three years
|
Patients are followed up in the outpatient department or by phone every six months, and the necessary medical history records are collected, including symptoms such as shortness of breath and signs such as lower extremity edema, measurement of brain natriuretic peptide levels, and treatment with diuretics, etc.
|
semi-annually, for a total of three years
|
|
heart transplantation
Prazo: semi-annually, for a total of three years
|
Patients are followed up in the outpatient department or by phone every six months, and the necessary medical history records are collected.
|
semi-annually, for a total of three years
|
Colaboradores e Investigadores
Colaboradores
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- ChiCTR2600117097 (Outro identificador: The First Affiliated Hospital of Anhui Medical University)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .